A Phase 1 interventional study of PF-06647020 Q3W and fluconazole in Neoplasms, sponsored by Pfizer. Completed at 17 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2020-12-17.
Sponsored by Pfizer · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
To assess the safety and tolerability at increasing dose levels of PF-06647020 in patients with advanced solid tumors in order to determine the maximum tolerated dose and select the recommended Phase 2 dose.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 138 is above the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Pfizer is the lead sponsor of 3,337 studies on the registry; 150 are open to participants now.
Of its 601 completed or terminated interventional studies of FDA-regulated products, 392 (65%) have results posted.
Counted across the registry records on this site, refreshed daily.
Q2W Inclusion Criteria:
Q2W Exclusion Criteria:
Q3W Inclusion Criteria:
Q3W Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Relapsed and refractory
Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Brain metastases
Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).
Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug infused over 60 minutes once every 21 days.
Drug: PF-06647020 Q3W
PF-06647020 combined with fluconazole
Drug: fluconazole
Investigational drug infused over 60 minutes once every 14 days (28 day cycle)
Drug: PF-06647020 Q2W
PF-06647020 combined with Avelumab administered by infusion
Drug: PF-06647020 combined with Avelumab
Part 1: PF-06647020 will be administered intravenously every 21 days in cohorts of 2-4 patients starting at a dose of 0.20mg/kg. Increases in dose will continue until MTD is determined. Part 2: Patients with triple negative breast cancer (pre-selected for PTK7 moderately high to high expression), non small cell lung cancer (pre-selected with moderate to high PTK7 expression) and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.
combination drug used for drug-drug interaction sub-study
Part 1: PF-06647020 will be administered intravenously every 14 days in cohorts of 2-4 patients starting at a dose of 2.1 mg/kg. Increases in dose will continue until MTD is determined. Part 2: Patients with non-small cell lung cancer (pre-selected for PTK7 moderate to high expression and ovarian cancer patients (unselected for PTK7 expression) will be treated at the MTD or Recommended Phase 2 Dose selected in Part 1.
Drug page: Avelumab
Part 2: Patients with ovarian cancer (unselected for PTK7 expression) will be treated with PF-0664702 plus Avelumab.
Number of Participants With Dose Limiting Toxicities (DLTs) - Q3W Regimen
A DLT was any of the following adverse events(AEs) in the first cycle of treatment (within 21 days of first dose or until participant received second infusion if there were treatment delays). (1)Hematologic: including Grade 4 neutropenia lasting \>7 days; Febrile neutropenia; Grade \>=3 neutropenic infection; Grade 4 anemia; Grade \>=3 thrombocytopenia with clinically significant bleeding. (2) Hepatic, including Grade \>=3 serum bilirubin, hepatic transaminase or alkaline phosphatase; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>=3.0 x upper limit of normal (ULN) concurrent with elevation in bilirubin \>=2.0 x ULN; (3) Grade \>=3 non-hematologic, non-hepatic major organ toxicities; delayed by \>2 weeks in receiving the next scheduled cycle due to persisting toxicities attributable to PF-06647020. A participant was on study for at least 21 days to be evaluable for DLT observation, and could be replaced if they terminated study participation earlier than 21 days.
Time frame: First Cycle, Day 1 up to Day 21
Number of Participants With Treatment-Emergent Adverse Events (AEs) - Q3W Regimen (All-Causality)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.
Time frame: From the time the participant took the first dose of study medication through the participant's last visit. (approximately 32 months)
Number of Participants With Treatment-Emergent AEs - Q3W Regimen (Treatment-Related)
A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.
Time frame: From the time the participant took the first dose of study medication through the participant's last visit. (approximately 32 months)
Number of Participants With Treatment-Emergent AEs Categorized by Seriousness - Q3W Regimen (All-Causality and Treatment-Related)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication. All AEs were graded by the investigator according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.
Time frame: From the time the participant took the first dose of study medication through the participant's last visit. (approximately 32 months)
Number of Participants With Hematology Laboratory Abnormalities (All Cycles) - Q3W Regimen
Participants who experienced hematology laboratory test abnormalities were summarized according to worst toxicity grade observed for each hematology laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with hematology laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: absolute neutrophils, lymphopenia, white blood cell, anemia, platelets.
Time frame: From baseline to end of treatment (approximately 32 months).
Number of Participants With Chemistry Laboratory Abnormalities (All Cycles) - Q3W Regimen
Participants who experienced chemistry laboratory test abnormalities were summarized according to worst toxicity grade observed for each chemistry laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with chemistry laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: hypokalemia, hypophosphatemia, aspartate aminotransferase, hyperglycemia, alkaline phosphatase, hyponatremia, alanine aminotransferase, hypoalbuminemia, total bilirubin, hypercalcemia, hypomagnesemia , creatinine, gamma glutamyl transferase, hypocalcemia.
Time frame: From baseline to end of treatment (approximately 32 months).
Number of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q3W Regimen
Participants who experienced urinalysis laboratory test abnormalities were summarized according to worst toxicity grade observed for each urinalysis laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with urinalysis laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above.
Time frame: From baseline to end of treatment (approximately 32 months).
Number of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q3W Regimen
Participants who experienced coagulation laboratory test abnormalities were summarized according to worst toxicity grade observed for each coagulation laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with coagulation laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameter: partial thromboplastin time.
Time frame: From baseline to end of treatment (approximately 32 months).
Number of Participants With DLTs - Q2W Regimen
A DLT was any of the following AEs in the first cycle of treatment (within 28 days of first dose or until participant received second infusion if there were treatment delayed) in the single agent dose escalation. (1)Hematologic: including Grade 4 neutropenia lasting \>7 days; Febrile neutropenia; Grade \>=3 neutropenic infection; Grade 4 thrombocytopenia; treatment delay \>14 days because of hematologic AE; (2) Hepatic: including Grade\>=3 serum bilirubin, hepatic transaminase or alkaline phosphatase; ALT or AST\>=3.0 x ULN concurrent with elevation in bilirubin\>=2.0 x ULN; (3) Grade \>=3 non-hematologic, non-hepatic major organ toxicities; delayed by \>2 weeks in receiving the next scheduled cycle due to persisting toxicities attributable to PF-06647020. Grade \>=3 headache lasting \>48 hours in presence of supportive care. A participant was on study for at least 28 days to be evaluable for DLT observation, and could be replaced if they terminated study participation earlier than 28 days.
Time frame: First cycle, Day 1 up to Day 28
Number of Participants With Treatment-Emergent AEs - Q2W Regimen (All-Causality)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.
Time frame: From the time the participant took the first dose of study medication through the participant's last visit. (approximately 19 months)
Number of Participants With Treatment-Emergent AEs - Q2W Regimen (Treatment-Related)
A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.
Time frame: From the time the participant took the first dose of study medication through the participant's last visit. (approximately 19 months)
Number of Participants With Treatment-Emergent AEs Categorized by Seriousness - Q2W Regimen (All-Causality and Treatment-Related)
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication. All AEs were graded by the investigator according to the NCI CTCAE version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.
Time frame: From the time the participant took the first dose of study medication through the participant's last visit. (approximately 19 months)
Number of Participants With Hematology Laboratory Abnormalities (All Cycles) - Q2W Regimen
Participants who experienced hematology laboratory test abnormalities were summarized according to worst toxicity grade observed for each hematology laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with hematology laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: absolute neutrophils, lymphopenia, white blood cell, anemia.
Time frame: From baseline to end of treatment (approximately 19 months).
Number of Participants With Chemistry Laboratory Abnormalities (All Cycles) - Q2W Regimen
Participants who experienced chemistry laboratory test abnormalities were summarized according to worst toxicity grade observed for each chemistry laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with chemistry laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: hypokalemia, hyponatremia, hypomagnesemia, hypoalbuminemia, hypocalcemia, hypophosphatemia, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase.
Time frame: From baseline to end of treatment (approximately 19 months).
Number of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q2W Regimen
Participants who experienced urinalysis laboratory test abnormalities were summarized according to worst toxicity grade observed for each urinalysis laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with urinalysis laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above.
Time frame: Baseline and Day 1 of Cycle 1
Number of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q2W Regimen
Participants who experienced coagulation laboratory test abnormalities were summarized according to worst toxicity grade observed for each urinalysis laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with coagulation laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameter: prothrombin time international normalized ratio.
Time frame: From baseline to end of treatment (approximately 19 months).
Area Under the Concentration-Time Profile From Time 0 to Time Tau (AUCtau) for PF-06647020 - Q3W Regimen
Tau refers to the dosing interval and it equals to 504 hours for the Q3W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06647020 was determined using linear/log trapezoidal method.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Maximum Observed Serum Concentration (Cmax) for PF-06647020 -Q3W Regimen
Cmax is maximum observed serum concentration. Cmax for PF-06647020 was observed directly from data.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Clearance (CL) for PF-06647020 - Q3W Regimen
Clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance for PF-06647020 was calculated as dose/AUCinf for single dose and dose/AUCtau for multiple dose, where AUCinf was the area under the serum concentration-time profile from time 0 extrapolated to infinite time and AUCtau was the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing).
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Volume of Distribution at Steady State (Vss) for PF-06647020 - Q3W Regimen
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Terminal Half-Life (t1/2) for PF-06647020 - Q3W Regimen
Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Observed Accumulation Ratio (Rac) for PF-06647020 - Q3W Regimen
Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing). Rac=Cycle 4 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).
Time frame: pre-dose, 1, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 4 (21 days cycle).
Time for Cmax (Tmax) for PF-06647020 - Q3W Regimen
Tmax is the time for Cmax. Tmax for PF-06647020 was observed directly from data as time of first occurrence.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Area Under the Concentration-Time Profile From Time 0 to the Time of the Last Quantifiable Concentration (AUClast) for PF-06647020 - Q3W Regimen
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06647020 was determined using linear/log trapezoidal method.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Area Under the Concentration-Time Profile From Time 0 Extrapolated to Infinite Time (AUCinf) for PF-06647020 - Q3W Regimen
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf for PF-06647020 was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
AUCtau for PF-06380101 - Q3W Regimen
Tau refers to the dosing interval and it equals to 504 hours for the Q3W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06380101 was determined using linear/log trapezoidal method.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Cmax for PF-06380101 - Q3W Regimen
Cmax is maximum observed serum concentration. Cmax for PF-06380101 was observed directly from data.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
t1/2 for PF-06380101 - Q3W Regimen
Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Rac for PF-06380101 - Q3W Regimen
Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing). Rac=Cycle 4 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).
Time frame: pre-dose, 1, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 4 (21 days cycle).
Tmax for PF-06380101 - Q3W Regimen
Tmax is the time for Cmax. Tmax for PF-06380101 was observed directly from data as time of first occurrence.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
AUClast for PF-06380101 - Q3W Regimen
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06380101 was determined using linear/log trapezoidal method.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
AUCinf for PF-06380101 - Q3W Regimen
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf for PF-06380101 was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
AUCtau for hu6M024 mAb - Q3W Regimen
Tau refers to the dosing interval and it equals to 504 hours for the Q3W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for hu6M024 mAb was determined using linear/log trapezoidal method.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Cmax for hu6M024 mAb - Q3W Regimen
Cmax is maximum observed serum concentration. Cmax for hu6M024 mAb was observed directly from data.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
t1/2 for hu6M024 mAb - Q3W Regimen
Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Rac for hu6M024 mAb - Q3W Regimen
Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing). Rac=Cycle 4 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).
Time frame: pre-dose, 1, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 4 (21 days cycle).
Tmax for hu6M024 mAb - Q3W Regimen
Tmax is the time for Cmax. Tmax for hu6M024 mAb was observed directly from data as time of first occurrence.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
AUClast for hu6M024 mAb - Q3W Regimen
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for hu6M024 mAb was determined using linear/log trapezoidal method.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
AUCinf for hu6M024 mAb - Q3W Regimen
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf for hu6M024 mAb was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 4 (21 days cycle).
Number of Participants With Anti-Drug Antibodies (ADA) and Neutralizing Antibody (NAb) of PF-06647020 - Q3W Regimen
To evaluate the immunogenicity as measured by presence of ADA and NAb in participants treated with PF-06647020.
Time frame: Prior to the start of treatment on Day 1 of Cycle 1 up to end of treatment (approximately 31 months).
Percentage of Participants With Objective Response - Q3W Regimen
Percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).
Duration of Response - Q3W Regimen
Duration of response (DoR) was the time from first documentation of PR or CR to date of first documentation of progressive disease (PD) or death due to any cause. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.
Time frame: Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).
Disease Control Rate - Q3W Regimen
The disease control rate (DCR) was defined as the percentage of participants with a confirmed CR, PR, non-CR/non-PD or stable disease (SD) according to the appropriate analysis set. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).
Time to Progression - Q3W Regimen
Time to progression (TTP) was the time from start date to the date of the first documentation of PD. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.
Time frame: Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).
Progression Free Survival - Q3W Regimen
Progression free survival (PFS) was the time from randomization date to date of first documentation of PD or death due to any cause. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.
Time frame: Baseline, every 6 weeks from the start of treatment until disease progression, death or withdrawal from treatment (approximately 32 months).
Dose Normalized AUCinf [AUCinf(dn)] for PF-06647020 [DDI Sub-Study]
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf(dn) was defined as dose normalized AUCinf and calculated as AUCinf/dose.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Dose Normalized AUClast [AUClast(dn)] for PF-06647020 [DDI Sub-Study]
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast(dn) was defined as dose normalized AUClast and calculated as AUClast/dose.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Dose Normalized AUCtau [AUCtau(dn)] for PF-06647020 [DDI Sub-Study]
AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau(dn) was defined as dose normalized AUCtau and calculated as AUCtau/dose.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Dose Normalized Cmax [Cmax(dn)] for PF-06647020 [DDI Sub-Study]
Cmax is maximum observed serum concentration. Cmax(dn) was defined as dose normalized Cmax and calculated as Cmax/dose.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
AUCinf(dn) for PF-06380101 [DDI Sub-Study]
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf(dn) was defined as dose normalized AUCinf and calculated as AUCinf/dose.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
AUClast(dn) for PF-06380101 [DDI Sub-Study]
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast(dn) was defined as dose normalized AUClast and calculated as AUClast/dose.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
AUCtau(dn) for PF-06380101 [DDI Sub-Study]
AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau(dn) was defined as dose normalized AUCtau and calculated as AUCtau/dose.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Cmax(dn) for PF-06380101 [DDI Sub-Study]
Cmax is maximum observed serum concentration. Cmax(dn) was defined as dose normalized Cmax and calculated as Cmax/dose.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
AUCinf(dn) for hu6M024 mAb [DDI Sub-Study]
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf(dn) was defined as dose normalized AUCinf and calculated as AUCinf/dose.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
AUClast(dn) for hu6M024 mAb [DDI Sub-Study]
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast(dn) was defined as dose normalized AUClast and calculated as AUClast/dose.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
AUCtau(dn) for hu6M024 mAb [DDI Sub-Study]
AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau(dn) was defined as dose normalized AUCtau and calculated as AUCtau/dose.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
Cmax(dn) for hu6M024 mAb [DDI Sub-Study]
Cmax is maximum observed serum concentration. Cmax(dn) was defined as dose normalized Cmax and calculated as Cmax/dose.
Time frame: pre-dose, 1, 4, 24, 72, 168, 336 hours post-dose for Cycle 1 and Cycle 2 (21 days cycle).
AUCtau for PF-06647020 - Q2W Regimen
Tau refers to the dosing interval and it equals to 336 hours for the Q2W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06647020 was determined using linear/log trapezoidal method.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Cmax for PF-06647020 -Q2W Regimen
Cmax is maximum observed serum concentration. Cmax for PF-06647020 was observed directly from data.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Vss for PF-06647020 - Q2W Regimen
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
CL for PF-06647020 - Q2W Regimen
Clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance for PF-06647020 was calculated as dose/AUCinf for single dose and dose/AUCtau for multiple dose, where AUCinf was the area under the serum concentration-time profile from time 0 extrapolated to infinite time and AUCtau was the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing).
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
t1/2 for PF-06647020 - Q2W Regimen
Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Rac for PF-06647020 - Q2W Regimen
Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing). Rac= Cycle 3 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).
Time frame: pre-dose, end of infusion, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 3 (28 days cycle).
Tmax for PF-06647020 - Q2W Regimen
Tmax is the time for Cmax. Tmax for PF-06647020 was observed directly from data as time of first occurrence.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
AUClast for PF-06647020 - Q2W Regimen
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06647020 was determined using linear/log trapezoidal method.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
AUCinf for PF-06647020 - Q2W Regimen
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
AUCtau for PF-06380101 - Q2W Regimen
Tau refers to the dosing interval and it equals to 336 hours for the Q2W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06380101 was determined using linear/log trapezoidal method.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Cmax for PF-06380101 - Q2W Regimen
Cmax is maximum observed serum concentration. Cmax for PF-06380101 was observed directly from data.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
t1/2 for PF-06380101 - Q2W Regimen
Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Rac for PF-06380101 - Q2W Regimen
Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing). Rac= Cycle 3 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).
Time frame: pre-dose, end of infusion, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 3 (28 days cycle).
Tmax for PF-06380101 - Q2W Regimen
Tmax is the time for Cmax. Tmax for PF-06380101 was observed directly from data as time of first occurrence.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
AUClast for PF-06380101- Q2W Regimen
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06380101 was determined using linear/log trapezoidal method.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
AUCinf for PF-06380101- Q2W Regimen
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
AUCtau for hu6M024 mAb- Q2W Regimen
Tau refers to the dosing interval and it equals to 336 hours for the Q2W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for hu6M024 mA was determined using linear/log trapezoidal method.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Cmax for hu6M024 mAb -Q2W Regimen
Cmax is maximum observed serum concentration. Cmax for hu6M024 mAb was observed directly from data.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
t1/2 for hu6M024 mAb - Q2W Regimen
Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Rac for hu6M024 mAb - Q2W Regimen
Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing). Rac= Cycle 3 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).
Time frame: pre-dose, end of infusion, 4 hours post-dose on Day 1 of Cycle 1 and Day 1 of Cycle 3 (28 days cycle).
Tmax for hu6M024 mAb - Q2W Regimen
Tmax is the time for Cmax. Tmax for hu6M024 mAb was observed directly from data as time of first occurrence.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
AUClast for hu6M024 mAb - Q2W Regimen
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for hu6M024 mAb was determined using linear/log trapezoidal method.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
AUCinf for hu6M024 mAb - Q2W Regimen
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
Time frame: pre-dose, end of infusion, 4, 24, 72, 168 hours post-dose, Day 15 (pre-dose, end of infusion) for Cycle 1 and Cycle 3 (28 days cycle).
Number of Participants With ADA and NAb of PF-06647020 - Q2W Regimen
To evaluate the immunogenicity as measured by presence of ADA and NAb in participants treated with PF-06647020.
Time frame: 2 hours before the first dose up to 30 days after the last dose (approximately 18 months).
Percentage of Participants With Objective Response - Q2W Regimen
Percentage of participants with objective response based on assessment of CR or PR according to RECIST version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
Time frame: Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).
Duration of Response - Q2W Regimen
For participants with an objective response, duration of response (DoR) was the time from first documentation of PR or CR to date of first documentation of PD or death due to any cause. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.
Time frame: Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).
Disease Control Rate - Q2W Regimen
The disease control rate (DCR) was defined as the percentage of participants with a confirmed CR, PR or SD according to the appropriate analysis set. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
Time frame: Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).
Time to Progression - Q2W Regimen
Time to progression (TTP) was the time from start date to the date of the first documentation of PD. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.
Time frame: Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).
Progression Free Survival - Q2W Regimen
Progression free survival (PFS) was the time from randomization date to date of first documentation of PD or death due to any cause. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.
Time frame: Baseline, every 8 weeks from the start of study treatment until disease progression, death or withdrawal from treatment (approximately 19 months).
| Milestone | PF-06647020 0.2 mg/kg (Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|---|---|---|---|---|---|
| Started | 2 | 2 | 2 | 5 | 96 | 6 | 3 | 10 | 12 |
| Received treatment | 2 | 2 | 2 | 4 | 96 | 6 | 3 | 10 | 12 |
| Completed | 1 | 2 | 1 | 2 | 58 | 3 | 1 | 6 | 6 |
| Not completed | 1 | 0 | 1 | 3 | 38 | 3 | 2 | 4 | 6 |
| Withdrew: Death | 0 | 0 | 0 | 0 | 13 | 0 | 0 | 0 | 2 |
| Withdrew: Lost to follow-up | 0 | 0 | 1 | 0 | 9 | 1 | 0 | 0 | 0 |
| Withdrew: Other | 0 | 0 | 0 | 2 | 10 | 2 | 2 | 4 | 1 |
| Withdrew: Participant refused further follow-up | 1 | 0 | 0 | 1 | 6 | 0 | 0 | 0 | 3 |
A DLT was any of the following adverse events(AEs) in the first cycle of treatment (within 21 days of first dose or until participant received second infusion if there were treatment delays). (1)Hematologic: including Grade 4 neutropenia lasting \>7 days; Febrile neutropenia; Grade \>=3 neutropenic infection; Grade 4 anemia; Grade \>=3 thrombocytopenia with clinically significant bleeding. (2) Hepatic, including Grade \>=3 serum bilirubin, hepatic transaminase or alkaline phosphatase; alanine aminotransferase (ALT) or aspartate aminotransferase (AST) \>=3.0 x upper limit of normal (ULN) concurrent with elevation in bilirubin \>=2.0 x ULN; (3) Grade \>=3 non-hematologic, non-hepatic major organ toxicities; delayed by \>2 weeks in receiving the next scheduled cycle due to persisting toxicities attributable to PF-06647020. A participant was on study for at least 21 days to be evaluable for DLT observation, and could be replaced if they terminated study participation earlier than 21 days.
| Participants | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) - Q3W Regimen | 0 | 0 | 0 | 0 | 0 | 2 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A serious adverse event (SAE) was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.
| Participants | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| AEs | 2 | 2 | 2 | 4 | 96 | 6 |
| SAEs | 0 | 0 | 0 | 1 | 33 | 2 |
A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.
| Participants | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| AEs | 1 | 1 | 1 | 4 | 84 | 5 |
| SAEs | 0 | 0 | 0 | 1 | 9 | 0 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication. All AEs were graded by the investigator according to the National Cancer Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.
| Participants | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Grade 1 (all-causality) | 0 | 0 | 1 | 1 | 6 | 0 |
| Grade 2 (all-causality) | 1 | 2 | 0 | 2 | 18 | 1 |
| Grade 3 (all-causality) | 1 | 0 | 1 | 1 | 49 | 5 |
| Grade 4 (all-causality) | 0 | 0 | 0 | 0 | 14 | 0 |
| Grade 5 (all-causality) | 0 | 0 | 0 | 0 | 9 | 0 |
| Missing or Unknown (all-causality) | 0 | 0 | 0 | 0 | 0 | 0 |
| Grade 1 (treatment-related) | 0 | 1 | 1 | 1 | 23 | 1 |
| Grade 2 (treatment-related) | 0 | 0 | 0 | 3 | 21 | 1 |
| Grade 3 (treatment-related) | 1 | 0 | 0 | 0 | 28 | 3 |
| Grade 4 (treatment-related) | 0 | 0 | 0 | 0 | 12 | 0 |
| Grade 5 (treatment-related) | 0 | 0 | 0 | 0 | 0 | 0 |
| Missing or Unknown (treatment-related) | 0 | 0 | 0 | 0 | 0 | 0 |
Participants who experienced hematology laboratory test abnormalities were summarized according to worst toxicity grade observed for each hematology laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with hematology laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: absolute neutrophils, lymphopenia, white blood cell, anemia, platelets.
| Participants | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Absolute neutrophils | 0 | 0 | 0 | 1 | 28 | 2 |
| Lymphopenia | 1 | 1 | 0 | 0 | 21 | 2 |
| White blood cells | 0 | 0 | 0 | 0 | 18 | 1 |
| Anemia | 0 | 0 | 0 | 0 | 2 | 0 |
| Platelets | 0 | 0 | 0 | 0 | 2 | 0 |
Participants who experienced chemistry laboratory test abnormalities were summarized according to worst toxicity grade observed for each chemistry laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with chemistry laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: hypokalemia, hypophosphatemia, aspartate aminotransferase, hyperglycemia, alkaline phosphatase, hyponatremia, alanine aminotransferase, hypoalbuminemia, total bilirubin, hypercalcemia, hypomagnesemia , creatinine, gamma glutamyl transferase, hypocalcemia.
| Participants | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Hypokalemia | 0 | 0 | 0 | 0 | 8 | 1 |
| Hypophosphatemia | 0 | 0 | 0 | 0 | 8 | 1 |
| Aspartate aminotransferase | 0 | 0 | 0 | 0 | 6 | 0 |
| Hyperglycemia | 0 | 0 | 0 | 0 | 6 | 0 |
| Alkaline phosphatase | 0 | 0 | 0 | 0 | 6 | 0 |
| Hyponatremia | 1 | 0 | 0 | 0 | 4 | 0 |
| Alanine aminotransferase | 0 | 0 | 0 | 0 | 4 | 0 |
| Hypoalbuminemia | 0 | 0 | 0 | 0 | 3 | 0 |
| Total bilirubin | 0 | 0 | 0 | 0 | 2 | 0 |
| Hypercalcemia | 0 | 0 | 0 | 0 | 2 | 0 |
| Hypomagnesemia | 0 | 0 | 0 | 0 | 2 | 0 |
| Creatinine | 0 | 0 | 0 | 0 | 1 | 0 |
| Gamma glutamyl transferase | 0 | 0 | 0 | 0 | 1 | 0 |
| Hypocalcemia | 0 | 0 | 0 | 0 | 1 | 0 |
Participants who experienced urinalysis laboratory test abnormalities were summarized according to worst toxicity grade observed for each urinalysis laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with urinalysis laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above.
| Participants | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Number of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q3W Regimen | 0 | 0 | 0 | 0 | 0 | 0 |
Participants who experienced coagulation laboratory test abnormalities were summarized according to worst toxicity grade observed for each coagulation laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with coagulation laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameter: partial thromboplastin time.
| Participants | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Number of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q3W Regimen | 0 | 0 | 0 | 0 | 1 | 0 |
A DLT was any of the following AEs in the first cycle of treatment (within 28 days of first dose or until participant received second infusion if there were treatment delayed) in the single agent dose escalation. (1)Hematologic: including Grade 4 neutropenia lasting \>7 days; Febrile neutropenia; Grade \>=3 neutropenic infection; Grade 4 thrombocytopenia; treatment delay \>14 days because of hematologic AE; (2) Hepatic: including Grade\>=3 serum bilirubin, hepatic transaminase or alkaline phosphatase; ALT or AST\>=3.0 x ULN concurrent with elevation in bilirubin\>=2.0 x ULN; (3) Grade \>=3 non-hematologic, non-hepatic major organ toxicities; delayed by \>2 weeks in receiving the next scheduled cycle due to persisting toxicities attributable to PF-06647020. Grade \>=3 headache lasting \>48 hours in presence of supportive care. A participant was on study for at least 28 days to be evaluable for DLT observation, and could be replaced if they terminated study participation earlier than 28 days.
| Participants | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Number of Participants With DLTs - Q2W Regimen | 0 | 1 | 2 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.
| Participants | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| AEs | 3 | 10 | 12 |
| SAEs | 1 | 4 | 7 |
A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. An SAE was an AE resulting in any of the following outcomes or deemed significant for any other reason: death; initial or prolonged inpatient hospitalization; life-threatening experience (immediate risk of dying); persistent or significant disability/incapacity; congenital anomaly. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication.
| Participants | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| AEs | 3 | 10 | 12 |
| SAEs | 0 | 2 | 2 |
An AE was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. A treatment-related AE was any untoward medical occurrence attributed to study drug in a participant who received study drug. Treatment-emergent AEs were those with initial onset or increasing in severity after the first dose of study medication. All AEs were graded by the investigator according to the NCI CTCAE version 4.03. Grade 1 AEs are mild AEs; Grade 2 AEs are moderate AEs; Grade 3 AEs are severe AEs, Grade 4 AEs are life-threatening consequences and Grade 5 AEs are deaths related to AEs. Each AE was counted once for the participant in the most severe severity.
| Participants | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Grade 1 (all-causality) | 0 | 0 | 0 |
| Grade 2 (all-causality) | 2 | 3 | 2 |
| Grade 3 (all-causality) | 1 | 5 | 7 |
| Grade 4 (all-causality) | 0 | 2 | 2 |
| Grade 5 (all-causality) | 0 | 0 | 1 |
| Missing or Unknown (all-causality) | 0 | 0 | 0 |
| Grade 1 (treatment-related) | 0 | 0 | 0 |
| Grade 2 (treatment-related) | 3 | 4 | 5 |
| Grade 3 (treatment-related) | 0 | 4 | 6 |
| Grade 4 (treatment-related) | 0 | 2 | 1 |
| Grade 5 (treatment-related) | 0 | 0 | 0 |
| Missing or Unknown (treatment-related) | 0 | 0 | 0 |
Participants who experienced hematology laboratory test abnormalities were summarized according to worst toxicity grade observed for each hematology laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with hematology laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: absolute neutrophils, lymphopenia, white blood cell, anemia.
| Participants | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Absolute neutrophils | 0 | 3 | 5 |
| Lymphopenia | 0 | 0 | 4 |
| White blood cells | 0 | 2 | 2 |
| Anemia | 0 | 0 | 1 |
Participants who experienced chemistry laboratory test abnormalities were summarized according to worst toxicity grade observed for each chemistry laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with chemistry laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameters: hypokalemia, hyponatremia, hypomagnesemia, hypoalbuminemia, hypocalcemia, hypophosphatemia, alanine aminotransferase, aspartate aminotransferase, alkaline phosphatase.
| Participants | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Hypokalemia | 0 | 1 | 2 |
| Hyponatremia | 0 | 1 | 2 |
| Hypomagnesemia | 0 | 0 | 2 |
| Hypoalbuminemia | 0 | 1 | 1 |
| Hypocalcemia | 1 | 0 | 1 |
| Hypophosphatemia | 0 | 1 | 0 |
| Alanine aminotransferase | 0 | 0 | 1 |
| Aspartate aminotransferase | 0 | 0 | 1 |
| Alkaline phosphatase | 0 | 0 | 1 |
Participants who experienced urinalysis laboratory test abnormalities were summarized according to worst toxicity grade observed for each urinalysis laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with urinalysis laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above.
| Participants | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Number of Participants With Urinalysis Laboratory Abnormalities (All Cycles) - Q2W Regimen | 0 | 0 | 0 |
Participants who experienced coagulation laboratory test abnormalities were summarized according to worst toxicity grade observed for each urinalysis laboratory test. Laboratory abnormalities were graded by NCI CTCAE version 4.03. This outcome measure calculated the number of participants with coagulation laboratory abnormalities that were shifted from \<=Grade 2 at baseline to Grade 3 or above, including the following parameter: prothrombin time international normalized ratio.
| Participants | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Number of Participants With Coagulation Laboratory Abnormalities (All Cycles) - Q2W Regimen | 0 | 0 | 1 |
Tau refers to the dosing interval and it equals to 504 hours for the Q3W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06647020 was determined using linear/log trapezoidal method.
| microgram•hour/milliliter (µg•hr/mL) | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 4570 ± 30 | 4782 ± 61 | 6929 ± 80 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 4201 ± 95 | 5834 ± 60 | NA ± NA |
Cmax is maximum observed serum concentration. Cmax for PF-06647020 was observed directly from data.
| microgram/milliliter (µg/mL) | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 65.77 ± 25 | 79.77 ± 45 | 96.11 ± 47 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 55.41 ± 53 | 92.94 ± 50 | NA ± NA |
Clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance for PF-06647020 was calculated as dose/AUCinf for single dose and dose/AUCtau for multiple dose, where AUCinf was the area under the serum concentration-time profile from time 0 extrapolated to infinite time and AUCtau was the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing).
| Liter/hour (L/hr) | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 0.03464 ± 27 | 0.03956 ± 60 | 0.03694 ± 72 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 0.03640 ± 42 | 0.03121 ± 60 | NA ± NA |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
| Liter (L) | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 3.498 ± 26 | 3.199 ± 40 | 3.947 ± 52 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 3.230 ± 46 | 2.808 ± 47 | NA ± NA |
Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.
| day | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 3.600 ± 0.487 | 3.107 ± 1.161 | 3.514 ± 0.696 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 4.013 ± 2.891 | 4.007 ± 1.496 | NA ± NA |
Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing). Rac=Cycle 4 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).
| Ratio | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Observed Accumulation Ratio (Rac) for PF-06647020 - Q3W Regimen | NA ± NA | — | NA ± NA | 1.046 ± 61 | 1.094 ± 39 | NA ± NA |
Tmax is the time for Cmax. Tmax for PF-06647020 was observed directly from data as time of first occurrence.
| hour | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 2.48 (0.950 to 4.17) | 1.08 (0.950 to 70.3) | 2.49 (0.983 to 24.1) |
| Cycle 4, Multiple Dose | NA (NA to NA) | — | NA (NA to NA) | 3.05 (0.967 to 24.0) | 1.65 (0.917 to 48.2) | NA (NA to NA) |
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06647020 was determined using linear/log trapezoidal method.
| µg•hr/mL | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 4570 ± 30 | 4674 ± 63 | 4450 ± 198 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 4157 ± 98 | 5428 ± 83 | NA ± NA |
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf for PF-06647020 was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| µg•hr/mL | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 4637 ± 30 | 4829 ± 63 | 7052 ± 81 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 4312 ± 102 | 6086 ± 62 | NA ± NA |
Tau refers to the dosing interval and it equals to 504 hours for the Q3W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06380101 was determined using linear/log trapezoidal method.
| nanogram•hour/milliliter (ng•hr/mL) | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 844.6 ± 46 | 803.9 ± 68 | 1022 ± 78 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 418.3 ± 106 | 647.9 ± 46 | NA ± NA |
Cmax is maximum observed serum concentration. Cmax for PF-06380101 was observed directly from data.
| nanogram/milliliter (ng/mL) | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 7.156 ± 39 | 6.934 ± 69 | 7.660 ± 47 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 3.379 ± 84 | 5.746 ± 60 | NA ± NA |
Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.
| day | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 3.150 ± 0.426 | 2.881 ± 0.604 | 3.210 ± 0.473 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 2.827 ± 0.391 | 2.781 ± 0.676 | NA ± NA |
Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing). Rac=Cycle 4 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).
| Ratio | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Rac for PF-06380101 - Q3W Regimen | NA ± NA | — | NA ± NA | 0.5454 ± 40 | 0.8916 ± 41 | NA ± NA |
Tmax is the time for Cmax. Tmax for PF-06380101 was observed directly from data as time of first occurrence.
| hour | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 23.6 (4.00 to 48.0) | 23.9 (3.90 to 141) | 23.4 (4.00 to 74.0) |
| Cycle 4, Multiple Dose | NA (NA to NA) | — | NA (NA to NA) | 23.8 (23.6 to 24.0) | 21.9 (3.67 to 96.0) | NA (NA to NA) |
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06380101 was determined using linear/log trapezoidal method.
| ng•hr/mL | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 844.6 ± 46 | 799.3 ± 68 | 490.5 ± 615 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 418.5 ± 106 | 643.6 ± 48 | NA ± NA |
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf for PF-06380101 was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| ng•hr/mL | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 851.4 ± 45 | 812.2 ± 68 | 1020 ± 95 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 422.9 ± 105 | 645.2 ± 48 | NA ± NA |
Tau refers to the dosing interval and it equals to 504 hours for the Q3W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for hu6M024 mAb was determined using linear/log trapezoidal method.
| µg•hr/mL | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 6968 ± 32 | 5562 ± 62 | 8451 ± 78 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 6122 ± 145 | 6210 ± 80 | NA ± NA |
Cmax is maximum observed serum concentration. Cmax for hu6M024 mAb was observed directly from data.
| µg/mL | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 83.33 ± 20 | 84.83 ± 43 | 99.37 ± 47 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 77.76 ± 76 | 82.33 ± 40 | NA ± NA |
Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.
| day | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 4.505 ± 0.650 | 3.674 ± 1.512 | 4.386 ± 0.895 |
| Cycle 4, Multiple Dose | — | — | NA ± NA | 5.087 ± 2.626 | 5.232 ± 2.259 | NA ± NA |
Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 504 hours for the Q3W dosing). Rac=Cycle 4 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).
| Ratio | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Rac for hu6M024 mAb - Q3W Regimen | NA ± NA | — | NA ± NA | 1.022 ± 108 | 0.9865 ± 48 | NA ± NA |
Tmax is the time for Cmax. Tmax for hu6M024 mAb was observed directly from data as time of first occurrence.
| hour | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA (NA to NA) | NA (NA to NA) | NA (NA to NA) | 4.00 (0.950 to 4.17) | 3.70 (0.933 to 24.1) | 2.31 (0.983 to 4.00) |
| Cycle 4, Multiple Dose | NA (NA to NA) | — | NA (NA to NA) | 3.05 (1.00 to 23.6) | 3.90 (1.00 to 41.8) | NA (NA to NA) |
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for hu6M024 mAb was determined using linear/log trapezoidal method.
| µg•hr/mL | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 6969 ± 32 | 5449 ± 64 | 5247 ± 221 |
| Cycle 4, Multiple Dose | NA ± NA | — | NA ± NA | 6127 ± 147 | 5885 ± 97 | NA ± NA |
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf for hu6M024 mAb was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| µg•hr/mL | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | NA ± NA | NA ± NA | 7189 ± 32 | 5608 ± 65 | 8760 ± 80 |
| Cycle 4, Multiple Dose | — | — | NA ± NA | 6517 ± 156 | 6191 ± 94 | NA ± NA |
To evaluate the immunogenicity as measured by presence of ADA and NAb in participants treated with PF-06647020.
| Participants | PF-06647020 0.2 mg/kg(Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) |
|---|---|---|---|---|---|---|
| Overall incidence of ADA | 1 | 0 | 0 | 0 | 10 | 0 |
| Overall incidence of NAb | 1 | 0 | 0 | 0 | 9 | 0 |
Percentage of participants with objective response based on assessment of complete response (CR) or partial response (PR) according to Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
| Percentage of participants | NSCLC - Q3W Regimen | OVCA - Q3W Regimen | TNBC - Q3W Regimen |
|---|---|---|---|
| Percentage of Participants With Objective Response - Q3W Regimen | 16.0 (4.5 to 36.1) | 27.3 (15.0 to 42.8) | 20.7 (8.0 to 39.7) |
Duration of response (DoR) was the time from first documentation of PR or CR to date of first documentation of progressive disease (PD) or death due to any cause. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.
| month | NSCLC - Q3W Regimen | OVCA - Q3W Regimen | TNBC - Q3W Regimen |
|---|---|---|---|
| Duration of Response - Q3W Regimen | 5.7 (1.5 to 9.9) | 4.2 (2.8 to 8.3) | 4.3 (1.3 to 10.2) |
The disease control rate (DCR) was defined as the percentage of participants with a confirmed CR, PR, non-CR/non-PD or stable disease (SD) according to the appropriate analysis set. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| Percentage of participants | NSCLC - Q3W Regimen | OVCA - Q3W Regimen | TNBC - Q3W Regimen |
|---|---|---|---|
| Disease Control Rate - Q3W Regimen | 56.0 (34.93 to 75.60) | 72.7 (57.21 to 85.04) | 48.3 (29.45 to 67.47) |
Time to progression (TTP) was the time from start date to the date of the first documentation of PD. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.
| month | NSCLC - Q3W Regimen | OVCA - Q3W Regimen | TNBC - Q3W Regimen |
|---|---|---|---|
| Time to Progression - Q3W Regimen | 2.9 (1.4 to 6.1) | 3.1 (2.3 to 5.5) | 2.2 (1.4 to 5.5) |
Progression free survival (PFS) was the time from randomization date to date of first documentation of PD or death due to any cause. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.
| month | NSCLC - Q3W Regimen | OVCA - Q3W Regimen | TNBC - Q3W Regimen |
|---|---|---|---|
| Progression Free Survival - Q3W Regimen | 2.9 (1.4 to 6.1) | 2.9 (2.3 to 5.5) | 1.5 (1.4 to 4.3) |
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf(dn) was defined as dose normalized AUCinf and calculated as AUCinf/dose.
| µg•hr/mL/mg | PF-06647020 2.8 mg/kg (Q3W-DDI) | PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) |
|---|---|---|
| Dose Normalized AUCinf [AUCinf(dn)] for PF-06647020 [DDI Sub-Study] | 29.56 ± 46 | 23.47 ± 53 |
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast(dn) was defined as dose normalized AUClast and calculated as AUClast/dose.
| µg•hr/mL/mg | PF-06647020 2.8 mg/kg (Q3W-DDI) | PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) |
|---|---|---|
| Dose Normalized AUClast [AUClast(dn)] for PF-06647020 [DDI Sub-Study] | 31.51 ± 51 | 24.34 ± 50 |
AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau(dn) was defined as dose normalized AUCtau and calculated as AUCtau/dose.
| µg•hr/mL/mg | PF-06647020 2.8 mg/kg (Q3W-DDI) | PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) |
|---|---|---|
| Dose Normalized AUCtau [AUCtau(dn)] for PF-06647020 [DDI Sub-Study] | 29.25 ± 46 | 24.85 ± 48 |
Cmax is maximum observed serum concentration. Cmax(dn) was defined as dose normalized Cmax and calculated as Cmax/dose.
| µg/mL/mg | PF-06647020 2.8 mg/kg (Q3W-DDI) | PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) |
|---|---|---|
| Dose Normalized Cmax [Cmax(dn)] for PF-06647020 [DDI Sub-Study] | 0.5010 ± 49 | 0.4425 ± 39 |
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf(dn) was defined as dose normalized AUCinf and calculated as AUCinf/dose.
| ng•hr/mL/mg | PF-06647020 2.8 mg/kg (Q3W-DDI) | PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) |
|---|---|---|
| AUCinf(dn) for PF-06380101 [DDI Sub-Study] | 5.787 ± 116 | 5.275 ± 123 |
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast(dn) was defined as dose normalized AUClast and calculated as AUClast/dose.
| ng•hr/mL/mg | PF-06647020 2.8 mg/kg (Q3W-DDI) | PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) |
|---|---|---|
| AUClast(dn) for PF-06380101 [DDI Sub-Study] | 5.681 ± 112 | 5.089 ± 128 |
AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau(dn) was defined as dose normalized AUCtau and calculated as AUCtau/dose.
| ng•hr/mL/mg | PF-06647020 2.8 mg/kg (Q3W-DDI) | PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) |
|---|---|---|
| AUCtau(dn) for PF-06380101 [DDI Sub-Study] | 5.746 ± 115 | 5.239 ± 123 |
Cmax is maximum observed serum concentration. Cmax(dn) was defined as dose normalized Cmax and calculated as Cmax/dose.
| ng/mL/mg | PF-06647020 2.8 mg/kg (Q3W-DDI) | PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) |
|---|---|---|
| Cmax(dn) for PF-06380101 [DDI Sub-Study] | 0.04336 ± 113 | 0.04436 ± 118 |
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf(dn) was defined as dose normalized AUCinf and calculated as AUCinf/dose.
| µg•hr/mL/mg | PF-06647020 2.8 mg/kg (Q3W-DDI) | PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) |
|---|---|---|
| AUCinf(dn) for hu6M024 mAb [DDI Sub-Study] | 31.94 ± 45 | 25.92 ± 46 |
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast(dn) was defined as dose normalized AUClast and calculated as AUClast/dose.
| µg•hr/mL/mg | PF-06647020 2.8 mg/kg (Q3W-DDI) | PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) |
|---|---|---|
| AUClast(dn) for hu6M024 mAb [DDI Sub-Study] | 31.30 ± 44 | 26.30 ± 48 |
AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau(dn) was defined as dose normalized AUCtau and calculated as AUCtau/dose.
| µg•hr/mL/mg | PF-06647020 2.8 mg/kg (Q3W-DDI) | PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) |
|---|---|---|
| AUCtau(dn) for hu6M024 mAb [DDI Sub-Study] | 31.29 ± 44 | 26.96 ± 46 |
Cmax is maximum observed serum concentration. Cmax(dn) was defined as dose normalized Cmax and calculated as Cmax/dose.
| µg/mL/mg | PF-06647020 2.8 mg/kg (Q3W-DDI) | PF-06647020 1.4 mg/kg + Fluconazole (Q3W-DDI) |
|---|---|---|
| Cmax(dn) for hu6M024 mAb [DDI Sub-Study] | 0.4378 ± 59 | 0.3885 ± 37 |
Tau refers to the dosing interval and it equals to 336 hours for the Q2W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06647020 was determined using linear/log trapezoidal method.
| µg•hr/mL | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 3627 ± 62 | 6541 ± 38 | 6319 ± 45 |
| Cycle 3, Multiple Dose | NA ± NA | 9858 ± 21 | 6933 ± 43 |
Cmax is maximum observed serum concentration. Cmax for PF-06647020 was observed directly from data.
| µg/mL | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 97.79 ± 14 | 99.69 ± 32 | 90.28 ± 32 |
| Cycle 3, Multiple Dose | NA ± NA | 114.7 ± 26 | 81.91 ± 34 |
Volume of distribution is defined as the theoretical volume in which the total amount of drug would need to be uniformly distributed to produce the desired blood concentration of a drug. Steady state volume of distribution (Vss) is the apparent volume of distribution at steady-state.
| Liter | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | 2.566 ± 44 | 2.953 ± 36 |
| Cycle 3, Multiple Dose | NA ± NA | 2.349 ± 24 | 3.106 ± 32 |
Clearance (CL) is a quantitative measure of the rate at which a drug substance is removed from the body. Clearance for PF-06647020 was calculated as dose/AUCinf for single dose and dose/AUCtau for multiple dose, where AUCinf was the area under the serum concentration-time profile from time 0 extrapolated to infinite time and AUCtau was the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing).
| L/hr | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | 0.03075 ± 49 | 0.03238 ± 39 |
| Cycle 3, Multiple Dose | NA ± NA | 0.02044 ± 25 | 0.02688 ± 35 |
Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.
| day | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | 2.700 ± 0.625 | 2.874 ± 0.385 |
| Cycle 3, Multiple Dose | NA ± NA | 3.633 ± 0.415 | 3.600 ± 0.583 |
Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing). Rac= Cycle 3 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).
| Ratio | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Rac for PF-06647020 - Q2W Regimen | NA ± NA | 1.425 ± 35 | 1.211 ± 18 |
Tmax is the time for Cmax. Tmax for PF-06647020 was observed directly from data as time of first occurrence.
| hour | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 3.98 (0.983 to 4.02) | 2.45 (0.983 to 23.7) | 1.05 (0.900 to 4.00) |
| Cycle 3, Multiple Dose | NA (NA to NA) | 1.07 (0.983 to 23.9) | 2.36 (0.983 to 4.03) |
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06647020 was determined using linear/log trapezoidal method.
| µg•hr/mL | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 3641 ± 62 | 6490 ± 39 | 6342 ± 46 |
| Cycle 3, Multiple Dose | NA ± NA | 9864 ± 20 | 7000 ± 43 |
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| µg•hr/mL | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | 6798 ± 41 | 6535 ± 46 |
| Cycle 3, Multiple Dose | NA ± NA | 10570 ± 22 | 7445 ± 44 |
Tau refers to the dosing interval and it equals to 336 hours for the Q2W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for PF-06380101 was determined using linear/log trapezoidal method.
| ng•hr/mL | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 568.9 ± 12 | 860.3 ± 52 | 740.5 ± 62 |
| Cycle 3, Multiple Dose | NA ± NA | 731.5 ± 61 | 589.8 ± 33 |
Cmax is maximum observed serum concentration. Cmax for PF-06380101 was observed directly from data.
| ng/mL | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 6.084 ± 59 | 6.665 ± 49 | 5.779 ± 59 |
| Cycle 3, Multiple Dose | NA ± NA | 4.857 ± 66 | 4.248 ± 34 |
Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.
| day | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 2.507 ± 0.411 | 2.646 ± 0.453 | 2.592 ± 0.331 |
| Cycle 3, Multiple Dose | NA ± NA | 2.755 ± 0.653 | 3.007 ± 0.373 |
Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing). Rac= Cycle 3 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).
| Ratio | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Rac for PF-06380101 - Q2W Regimen | NA ± NA | 0.9980 ± 26 | 0.9657 ± 25 |
Tmax is the time for Cmax. Tmax for PF-06380101 was observed directly from data as time of first occurrence.
| hour | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 3.98 (3.98 to 4.02) | 4.05 (3.75 to 72.1) | 24.7 (3.72 to 48.5) |
| Cycle 3, Multiple Dose | NA (NA to NA) | 71.7 (3.75 to 166) | 22.8 (3.75 to 48.3) |
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for PF-06380101 was determined using linear/log trapezoidal method.
| ng•hr/mL | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 569.9 ± 12 | 866.0 ± 53 | 743.5 ± 63 |
| Cycle 3, Multiple Dose | NA ± NA | 728.9 ± 60 | 593.3 ± 33 |
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| ng•hr/mL | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 584.4 ± 11 | 888.5 ± 54 | 763.2 ± 62 |
| Cycle 3, Multiple Dose | NA ± NA | 738.8 ± 69 | 617.9 ± 32 |
Tau refers to the dosing interval and it equals to 336 hours for the Q2W dosing. AUCtau is the area under the concentration-time profile from time 0 to time tau. AUCtau for hu6M024 mA was determined using linear/log trapezoidal method.
| µg•hr/mL | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 4089 ± 52 | 7325 ± 47 | 6911 ± 44 |
| Cycle 3, Multiple Dose | NA ± NA | 10440 ± 25 | 8432 ± 42 |
Cmax is maximum observed serum concentration. Cmax for hu6M024 mAb was observed directly from data.
| µg/mL | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 72.04 ± 23 | 102.1 ± 38 | 86.26 ± 27 |
| Cycle 3, Multiple Dose | NA ± NA | 106.6 ± 37 | 89.66 ± 33 |
Terminal half-life (t1/2) is the time measured for the plasma concentration of drug to decrease by one half.
| day | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | 3.436 ± 0.750 | 3.645 ± 0.752 |
| Cycle 3, Multiple Dose | NA ± NA | 4.734 ± 0.670 | 4.124 ± 1.218 |
Rac is defined as observed accumulation ratio based on dose normalized AUCtau (AUCtau\[dn\]), where AUCtau is the area under the concentration-time profile from time 0 to time tau (tau equals to 336 hours for the Q2W dosing). Rac= Cycle 3 Day 1 AUCtau(dn) (multiple dose) /Cycle 1 Day 1 AUCtau(dn) (single Dose).
| Ratio | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Rac for hu6M024 mAb - Q2W Regimen | NA ± NA | 1.280 ± 32 | 1.301 ± 35 |
Tmax is the time for Cmax. Tmax for hu6M024 mAb was observed directly from data as time of first occurrence.
| hour | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 3.98 (1.00 to 4.02) | 3.87 (0.983 to 4.35) | 1.05 (0.900 to 23.8) |
| Cycle 3, Multiple Dose | NA (NA to NA) | 1.05 (0.950 to 3.92) | 2.36 (0.983 to 24.1) |
AUClast is the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration. AUClast for hu6M024 mAb was determined using linear/log trapezoidal method.
| µg•hr/mL | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | 4103 ± 52 | 7368 ± 46 | 6949 ± 45 |
| Cycle 3, Multiple Dose | NA ± NA | 10460 ± 24 | 8555 ± 41 |
AUCinf is the area under the serum concentration-time profile from time 0 extrapolated to infinite time. AUCinf was calculated as AUClast + (Clast\*/kel), where AUClast was the area under the serum concentration-time profile from time 0 to the time of the last quantifiable concentration, Clast\* was the predicted serum concentration at the last quantifiable time point estimated from the log-linear regression analysis. kel was the terminal phase rate constant calculated by a linear regression of the log-linear concentration-time curve.
| µg•hr/mL | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Cycle 1, Single Dose | NA ± NA | 7742 ± 47 | 7411 ± 48 |
| Cycle 3, Multiple Dose | NA ± NA | 10950 ± 22 | 8275 ± 44 |
To evaluate the immunogenicity as measured by presence of ADA and NAb in participants treated with PF-06647020.
| Participants | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|
| Overall incidence of ADA | 1 | 0 | 0 |
| Overall incidence of NAb | 1 | 0 | 0 |
Percentage of participants with objective response based on assessment of CR or PR according to RECIST version 1.1. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions.
| Percentage of participants | NSCLC - Q2W Regimen | OVCA - Q2W Regimen |
|---|---|---|
| Percentage of Participants With Objective Response - Q2W Regimen | 33.3 (4.3 to 77.7) | 26.3 (9.1 to 51.2) |
For participants with an objective response, duration of response (DoR) was the time from first documentation of PR or CR to date of first documentation of PD or death due to any cause. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.
| month | NSCLC - Q2W Regimen | OVCA - Q2W Regimen |
|---|---|---|
| Duration of Response - Q2W Regimen | NA (3.7 to NA) | 6.5 (3.9 to 8.3) |
The disease control rate (DCR) was defined as the percentage of participants with a confirmed CR, PR or SD according to the appropriate analysis set. CR was defined as complete disappearance of all target lesions and non-target disease, with the exception of nodal disease. All nodes, both target and non-target, must decrease to normal (short axis \<10 mm). No new lesions. PR was defined as \>=30% decrease under baseline of the sum of diameters of all target lesions. The short axis was used in the sum for target nodes, while the longest diameter was used in the sum for all other target lesions. No unequivocal progression of non-target disease. No new lesions. SD was defined as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
| Percentage of participants | NSCLC - Q2W Regimen | OVCA - Q2W Regimen |
|---|---|---|
| Disease Control Rate - Q2W Regimen | 50 (11.81 to 88.19) | 84.2 (60.42 to 96.62) |
Time to progression (TTP) was the time from start date to the date of the first documentation of PD. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.
| month | NSCLC - Q2W Regimen | OVCA - Q2W Regimen |
|---|---|---|
| Time to Progression - Q2W Regimen | 2.7 (1.0 to NA) | 3.8 (3.1 to 7.4) |
Progression free survival (PFS) was the time from randomization date to date of first documentation of PD or death due to any cause. PD was defined as at least a 20% increase (including an absolute increase of at least 5 mm) in the sum of diameters of target lesions, taking as reference the smallest sum on study and/or unequivocal progression of existing non-target lesions and/or appearance of one or more new lesions.
| month | NSCLC - Q2W Regimen | OVCA - Q2W Regimen |
|---|---|---|
| Progression Free Survival - Q2W Regimen | 2.7 (1.0 to NA) | 3.8 (3.1 to 7.4) |
Collected over From the time the participant took the first dose of study medication through the participant's last visit.(approximately 32 months). Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| PF-06647020 0.2 mg/kg (Q3W Regimen) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| PF-06647020 0.5 mg/kg (Q3W Regimen) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| PF-06647020 1.25 mg/kg (Q3W Regimen) | 0/2 (0%) | 0/2 (0%) | 2/2 (100%) |
| PF-06647020 2.1 mg/kg (Q3W Regimen) | 0/4 (0%) | 1/4 (25%) | 4/4 (100%) |
| PF-06647020 2.8 mg/kg (Q3W Regimen) | 13/96 (13.5%) | 33/96 (34.4%) | 93/96 (96.9%) |
| PF-06647020 3.7 mg/kg (Q3W Regimen) | 0/6 (0%) | 2/6 (33.3%) | 6/6 (100%) |
| PF-06647020 2.1 mg/kg (Q2W Regimen) | 0/3 (0%) | 1/3 (33.3%) | 3/3 (100%) |
| PF-06647020 2.8 mg/kg (Q2W Regimen) | 0/10 (0%) | 4/10 (40%) | 10/10 (100%) |
| PF-06647020 3.2 mg/kg (Q2W Regimen) | 2/12 (16.7%) | 7/12 (58.3%) | 12/12 (100%) |
| Event | PF-06647020 0.2 mg/kg (Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|---|---|---|---|---|---|
| DiarrhoeaGastrointestinal disorders | 0/2 | 0/2 | 0/2 | 0/4 | 0/96 | 0/6 | 1/3 | 0/10 | 0/12 |
| VomitingGastrointestinal disorders | 0/2 | 0/2 | 0/2 | 1/4 | 2/96 | 0/6 | 0/3 | 1/10 | 1/12 |
| HeadacheNervous system disorders | 0/2 | 0/2 | 0/2 | 1/4 | 0/96 | 0/6 | 0/3 | 0/10 | 0/12 |
| Abdominal painGastrointestinal disorders | 0/2 | 0/2 | 0/2 | 0/4 | 1/96 | 0/6 | 0/3 | 2/10 | 2/12 |
| ConstipationGastrointestinal disorders | 0/2 | 0/2 | 0/2 | 0/4 | 3/96 | 1/6 | 0/3 | 1/10 | 0/12 |
| Mental status changesPsychiatric disorders | 0/2 | 0/2 | 0/2 | 0/4 | 1/96 | 1/6 | 0/3 | 0/10 | 0/12 |
| AnaemiaBlood and lymphatic system disorders | 0/2 | 0/2 | 0/2 | 0/4 | 1/96 | 0/6 | 0/3 | 1/10 | 0/12 |
| NauseaGastrointestinal disorders | 0/2 | 0/2 | 0/2 | 0/4 | 3/96 | 0/6 | 0/3 | 1/10 | 1/12 |
| LethargyNervous system disorders | 0/2 | 0/2 | 0/2 | 0/4 | 1/96 | 0/6 | 0/3 | 1/10 | 0/12 |
| Pleural effusionRespiratory, thoracic and mediastinal disorders | 0/2 | 0/2 | 0/2 | 0/4 | 3/96 | 0/6 | 0/3 | 1/10 | 0/12 |
| Event | PF-06647020 0.2 mg/kg (Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) |
|---|---|---|---|---|---|---|---|---|---|
| FatigueGeneral disorders | 1/2 | 0/2 | 2/2 | 2/4 | 51/96 | 3/6 | 0/3 | 5/10 | 7/12 |
| Tumour painNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/2 | 2/2 | 0/2 | 0/4 | 5/96 | 0/6 | 0/3 | 0/10 | 0/12 |
| AlopeciaSkin and subcutaneous tissue disorders | 0/2 | 0/2 | 1/2 | 1/4 | 41/96 | 3/6 | 3/3 | 8/10 | 7/12 |
| NauseaGastrointestinal disorders | 1/2 | 1/2 | 1/2 | 2/4 | 46/96 | 4/6 | 0/3 | 3/10 | 7/12 |
| ConstipationGastrointestinal disorders | 1/2 | 0/2 | 1/2 | 1/4 | 33/96 | 2/6 | 0/3 | 6/10 | 7/12 |
| HeadacheNervous system disorders | 0/2 | 0/2 | 0/2 | 2/4 | 35/96 | 3/6 | 0/3 | 4/10 | 7/12 |
| PalpitationsCardiac disorders | 0/2 | 0/2 | 1/2 | 0/4 | 3/96 | 0/6 | 0/3 | 2/10 | 0/12 |
| Pericardial effusionCardiac disorders | 0/2 | 0/2 | 1/2 | 0/4 | 1/96 | 0/6 | 0/3 | 0/10 | 0/12 |
| Sinus tachycardiaCardiac disorders | 0/2 | 0/2 | 1/2 | 0/4 | 2/96 | 0/6 | 0/3 | 0/10 | 0/12 |
| Abdominal painGastrointestinal disorders | 0/2 | 0/2 | 1/2 | 0/4 | 15/96 | 1/6 | 0/3 | 4/10 | 6/12 |
Baseline analysis population included all enrolled participants who received at least 1 full or partial dose of study medication.
| Age, Continuous(Years) | PF-06647020 0.2 mg/kg (Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3W Regimen | 73.0 ± 2.8 | 57.5 ± 14.8 | 61.0 ± 2.8 | 55.0 ± 13.6 | 58.1 ± 11.8 | 59.5 ± 8.4 | — | — | — | 58.4 ± 11.6 |
| Q2W Regimen | — | — | — | — | — | — | 64.0 ± 2.6 | 65.5 ± 8.9 | 65.6 ± 8.0 | 65.4 ± 7.8 |
| Age, Customized(Participants) | PF-06647020 0.2 mg/kg (Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| < 18 (Q3W Regimen) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18-44 (Q3W Regimen) | 0 | 0 | 0 | 0 | 16 | 0 | 0 | 0 | 0 | 16 |
| 45-64 (Q3W Regimen) | 0 | 1 | 2 | 3 | 49 | 4 | 0 | 0 | 0 | 59 |
| >= 65 (Q3W Regimen) | 2 | 1 | 0 | 1 | 31 | 2 | 0 | 0 | 0 | 37 |
| < 18 (Q2W Regimen) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 18-44 (Q2W Regimen) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| 45-64 (Q2W Regimen) | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 5 | 6 | 12 |
| >= 65 (Q2W Regimen) | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 5 | 6 | 13 |
| Sex: Female, Male(Participants) | PF-06647020 0.2 mg/kg (Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3W Regimen — Female | 2 | 1 | 1 | 3 | 80 | 5 | 0 | 0 | 0 | 92 |
| Q3W Regimen — Male | 0 | 1 | 1 | 1 | 16 | 1 | 0 | 0 | 0 | 20 |
| Q2W Regimen — Female | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 10 | 11 | 24 |
| Q2W Regimen — Male | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Race (NIH/OMB)(Participants) | PF-06647020 0.2 mg/kg (Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3W Regimen — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Q3W Regimen — Asian | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 1 |
| Q3W Regimen — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Q3W Regimen — Black or African American | 0 | 0 | 0 | 1 | 5 | 0 | 0 | 0 | 0 | 6 |
| Q3W Regimen — White | 2 | 2 | 2 | 3 | 88 | 6 | 0 | 0 | 0 | 103 |
| Q3W Regimen — More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Q3W Regimen — Unknown or Not Reported | 0 | 0 | 0 | 0 | 2 | 0 | 0 | 0 | 0 | 2 |
| Q2W Regimen — American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Q2W Regimen — Asian | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 |
| Q2W Regimen — Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Q2W Regimen — Black or African American | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 1 |
| Q2W Regimen — White | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 8 | 11 | 21 |
| Q2W Regimen — More than one race | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Q2W Regimen — Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | 2 |
| Weight Continuous(kilogram (kg)) | PF-06647020 0.2 mg/kg (Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3W Regimen | 49.2 ± 10.2 | 68.8 ± 21.9 | 68.7 ± 5.2 | 80.7 ± 27.3 | 69.9 ± 16.4 | 72.2 ± 14.2 | — | — | — | 70.0 ± 16.6 |
| Q2W Regimen | — | — | — | — | — | — | 68.4 ± 23.8 | 78.1 ± 25.5 | 68.3 ± 22.5 | 72.3 ± 23.4 |
| Body Mass Index (BMI) Continuous(kg/m^2) | PF-06647020 0.2 mg/kg (Q3W Regimen) | PF-06647020 0.5 mg/kg (Q3W Regimen) | PF-06647020 1.25 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q3W Regimen) | PF-06647020 2.8 mg/kg (Q3W Regimen) | PF-06647020 3.7 mg/kg (Q3W Regimen) | PF-06647020 2.1 mg/kg (Q2W Regimen) | PF-06647020 2.8 mg/kg (Q2W Regimen) | PF-06647020 3.2 mg/kg (Q2W Regimen) | Total |
|---|---|---|---|---|---|---|---|---|---|---|
| Q3W Regimen | 18.3 ± 2.0 | 22.7 ± 2.7 | 23.6 ± 2.0 | 27.6 ± 7.7 | 25.6 ± 5.5 | 26.2 ± 4.7 | — | — | — | 25.5 ± 5.5 |
| Q2W Regimen | — | — | — | — | — | — | 24.9 ± 7.1 | 29.9 ± 9.1 | 25.6 ± 8.8 | 27.2 ± 8.7 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No — Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests.
Ran from Oct 2014 to primary completion in Nov 2019, 60 months.
Results were first posted in Dec 2020, 1 year 1 month after primary completion.
Of 677 industry-sponsored phase 1 interventional studies under Neoplasms, half reached primary completion within 38 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 62. This study's 60 months is above that.
Counting every sponsor, half of 904 studies reached it within 40 months; a quarter within 23 and three quarters within 64.
Neoplasms covers many different conditions, not one, so the studies compared here vary widely. Read these figures as a rough guide.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Dec 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluconazole · Avelumab